Skip to main content
Premium Trial:

Request an Annual Quote

NIPD Firm KellBenX Raises $10M in Series C Round

NEW YORK (GenomeWeb News) – Non-invasive prenatal diagnostics firm KellBenX has closed on a $10 million Series C financing round, its Co-Founder and CEO Hassan Bennani GenomeWeb Daily News today.

The financing was raised by a new investor that Bennani declined to identify, and will be used to accelerate clinical trials for its technology. Since its inception, it has raised $15 million.

The Great River, NY-based company, founded in 2010, is building a blood-based assay that can separate rare fetal cells in maternal blood. Its technology is based on antibody called 4B9 licensed from AdnaGen. 4B9 recognizes and binds to an epitope expressed by a type of nucleated fetal nucleated red blood cell, or fNRBC.

KellBenX plans to launch its test in late 2014 or early 2015.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.